Literature DB >> 7903313

Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.

C A Jaffe1, P J Ho, R Demott-Friberg, C Y Bowers, A L Barkan.   

Abstract

Bolus injection of the synthetic hexapeptide GH-releasing peptide-6 (GHRP-6) reliably promotes GH secretion. However, desensitization to the GH-releasing effects of GHRP has been shown to occur during short term iv infusion. To determine whether humans would remain responsive to prolonged exposure to GHRP and to study the mechanism of action of GHRP, we compared the effects of a 34-h iv infusion of either GHRP or normal saline on parameters of pulsatile GH concentration in nine healthy young men. Each infusion was administered from 0800 h on day 1 to 1800 h on day 2. GHRP was given as a 1 microgram/kg loading bolus, then at the rate of 1 microgram/kg.h. A 50-microgram iv bolus of TRH was given at 0800 h on day 2, followed by iv boluses of GH-releasing hormone (GHRH; 1 microgram/kg, iv, at 1000, 1200, and 1400 h) and then a bolus of GHRP (1 microgram/kg at 1600 h). The integrated GH concentration (IGHC) and parameters of pulsatile GH concentration were calculated for the period between 1400 h on day 1 to 0800 h on day 2, and IGHC was calculated for 2 h after each bolus of GHRP or GHRH. During GHRP infusion, there was a significant increase in IGHC (2908 +/- 450 vs. 1374 +/- 160 micrograms x min/L), maximum pulse amplitude (15.2 +/- 2.8 vs. 8.4 +/- 1.7 micrograms/L), and mean pulse amplitude (7.0 +/- 1.1 vs. 3.8 +/- 1.5 micrograms/L). Plasma insulin-like growth factor-I increased from 252 +/- 23 to 312 +/- 23 micrograms/L. There was no change in either GH pulse frequency or interpulse GH concentration. During GHRP infusion, the GH responses to the GHRH boluses were augmented; however, baseline TSH was lower, and the GH and TSH/PRL responses to GHRP and TRH, respectively, were smaller. We conclude that the pituitary remains sensitive to GHRP during a prolonged GHRP infusion. The mechanisms of the GHRP effect on GH secretion are uncertain, and the possibility that GHRP acts as a functional somatostatin antagonist is discussed. The contrasting effects of GHRP on GH and TSH/PRL secretion could be due to differential effects of GHRP on the pituitary and hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903313     DOI: 10.1210/jcem.77.6.7903313

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  The Safety and Efficacy of Growth Hormone Secretagogues.

Authors:  John T Sigalos; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-04-08

2.  Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.

Authors:  C Y Bowers; R Granda-Ayala
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 3.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 4.  Insulin-like growth factor 1 (IGF-1): a growth hormone.

Authors:  Z Laron
Journal:  Mol Pathol       Date:  2001-10

5.  The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone.

Authors:  L K Conley; R S Brogan; A Giustina; W B Wehrenberg
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

6.  Lack of effect of hexarelin on TRH-induced TSH response in normal adult man.

Authors:  M Arosio; G Casati; O Biella; S Porretti; B P Imbimbo; G Faglia
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

7.  Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro.

Authors:  R D Orkin; D I New; D Norman; S L Chew; A J L Clark; A B Grossman; M Korbonits
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

Review 8.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 9.  Growth hormone secretagogues. Clinical experience and therapeutic potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

10.  Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.

Authors:  C A Jaffe; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.